Foghorn Therapeutics updates pipeline progress and cash position in Q3 2026 report
The company reported preclinical advances in its IBD and EP300 degrader programs alongside $156.2 million in cash and runway into the second half of 2029.
SEC filing
2 stories
The company reported preclinical advances in its IBD and EP300 degrader programs alongside $156.2 million in cash and runway into the second half of 2029.
SEC filing
Foghorn Therapeutics said it will not advance FHD-909 with Eli Lilly into expansion after Phase 1 data, and is reducing staff to focus on its own pipeline.
SEC filing